glucagon receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Other steps include the isolation of various security agencies to ensure that a synchronised attack could not succeed on all fronts and the planned appointment of a National Cyber Security Coordinator. As of that month, there had been no significant economic or physical damage to India related to cyber attacks. On 26 November 2010, a group calling itself the Indian Cyber Army hacked the websites belonging to the Pakistan Army and the others belong to different ministries, including the Ministry of Foreign Affairs, Ministry of Education, Ministry of Finance, Pakistan Computer Bureau, Council of Islamic Ideology, etc. The attack was done as a revenge for the Mumbai terrorist attacks. On 4 December 2010, a group calling itself the Pakistan Cyber Army hacked the website of India's top investigating agency, the Central Bureau of Investigation (CBI). The National Informatics Center (NIC) has begun an inquiry. In July 2016, Cymmetria researchers discovered and revealed the cyber attack dubbed 'Patchwork', which compromised an estimated 2500 corporate and government agencies using code stolen from GitHub and the dark web. Examples of weapons used are an exploit for the Sandworm vulnerability (CVE-2014–4114), a compiled AutoIt script, and UAC bypass code dubbed UACME. Targets are believed to be mainly military and political assignments around Southeast Asia and the South China Sea and the attackers are believed to be of Indian origin and gathering intelligence from influential parties.
=== An–At === Rudolph John Anderson (1879–1961). American biochemist graduated with a PhD from Cornell University Medical College. Member Natl. Acad. Sci. USA. Thomas F. Anderson (1911–1991). American biophysical chemist and geneticist at the University of Pennsylvania, a pioneer in applying electron microscopy to bacteria and viruses. Member Natl. Acad. Sci. USA. Mortimer Louis Anson (1901–1968). American biochemist and protein chemist, the first to propose that protein folding was reversible. Akira Arimura (1923–2007). Japanese biochemist and endocrinologist at Tulane University who studied hormones. Shy Arkin (b. 1965). Israeli biochemist at the Hebrew University of Jerusalem, working on structural analysis of transmembrane proteins Judy Armitage FRS (b. 1951). British biochemist at Oxford University, working on motion of bacteria by flagellar rotation. Frances Arnold (b. 1956). American biochemist and biochemical engineer at Caltech, pioneer of the use of directed evolution to engineer enzymes. Nobel Prize for Chemistry (2018). Member Natl. Acad. Sci. USA. Ruth Arnon (b. 1933) Israeli biochemist at the Weizmann Institute, who works on researching anti-cancer and influenza vaccinations. She participated in developing the multiple sclerosis drug Copaxone. President of the Israel Academy of Sciences and Humanities. Helen Asemota (20th–21st century). Nigerian biochemist at the University of the West Indies, Jamaica, who studied the molecular genetics and metabolism of the browning of yam tubers in storage. Gilbert Ashwell (1916–2014).
One barn is 10−28 square metres, about the cross-sectional area of a uranium nucleus. The name probably derives from early neutron-deflection experiments, when the uranium nucleus was described, and the phrases "big as a barn" and "hit a barn door" were used. Barn are typically used for cross sections in nuclear and particle physics. Additional units include the microbarn (or "outhouse") and the yoctobarn (or "shed").
=== Sources to people === Food, drinking water, outdoor air, indoor air, dust, and food packagings are all implicated as sources of PFOA to people. However, it is unclear which exposure routes dominate because of data gaps. When water is a source, blood levels are approximately 100 times higher than drinking water levels. People who lived in the PFOA-contaminated area around DuPont's Washington Works facility were found to have higher levels of PFOA in their blood from drinking water. The highest PFOA levels in drinking water were found in the Little Hocking water system, with an average concentration of 3.55 parts per billion during 2002–2005. Individuals who drank more tap water, ate locally grown fruits and vegetables, or ate local meat, were all associated with having higher PFOA levels. Residents who used water carbon filter systems had lower PFOA levels. In Jersey, UK, 18% of residents of an area were found to have elevated levels of PFOA, downstream from 3M fire retardant tests in weekly fire-service practice from the 1960s to the mid 1990s. Bloodletting is used for these residents at a cost of $4500 per patient. The potatoes of the island were found to contain 10x the EU limit of PFOS.
The substances were more effective than placebo in the two studies included but the authors state that "the evidence was of insufficient quality to be conclusive" and note that "because alternative antidepressants exist which have been proven to be effective and safe, the clinical usefulness of 5-HTP and tryptophan is limited at present". The use of tryptophan as an adjunctive therapy in addition to standard treatment for mood and anxiety disorders is not supported by the scientific evidence.
Sources: en.wikipedia.org
=== MP for Henley: 1974–2001 === Heseltine, by now a junior minister in the Heath government, was now forced to apply for a new candidacy, often in competition with other sitting Conservative MPs whose seats were also due for abolition. He applied for Mid Sussex in competition with Ian Gilmour, but they lost to Tim Renton. He also applied for Mid-Oxfordshire but lost to Douglas Hurd. In 1972 Edward Heath attempted to persuade Heseltine, a strong supporter of his, to challenge Powellite MP Ronald Bell for the Conservative nomination for the new seat of Beaconsfield. Heseltine wrote that he was "tempted" to enter the lists at Beaconsfield, but did not actually do so. Crick writes that he reached the final shortlist of four against Bell, before being "apparently persuaded" to withdraw. Bell's campaign within the local Conservative ranks was masterminded by Hugh Simmonds, chairman of the Young Conservatives, and he narrowly won. Heseltine was one of 180 applicants for the safe Conservative seat of Henley (the constituency association of which was known as North Oxfordshire), whose MP John Hay was stepping down. He reached the final shortlist of three along with two other sitting MPs, William Shelton and Norman Fowler, and in September 1972 was selected as candidate with a clear majority at the first ballot. Part of the reason was that the Association wanted a wealthy MP who would not be distracted by the need to earn money in business as Hay had been. He maintained a constituency home in Crocker End, near Nettlebed, and still maintained a London home at Wilton Crescent.
Improving suppression of hemipteran vectors and bacterial pathogens of citrus and Solanaceous plants: Advances in Antisense Oligonucleotides (FANA). Front. Agron. 3:675247. doi:10.3389/fagro.2021.675247
=== Ligne === The ligne is a French unit of length that is sometimes used in watchmaking and ribbon manufacture. It is equal to one twelfth of a Paris inch, or about 2.2558 mm. Diameters of buttons are also measured in a unit called the ligne, but it is defined as 1/40 inch.
The most common gastrointestinal complications of anorexia nervosa are delayed stomach emptying and constipation, but also include elevated liver function tests, diarrhea, acute pancreatitis, gastroesophageal reflux disease (GERD), difficulty swallowing, and, rarely, superior mesenteric artery syndrome. Acid exposure from GERD and self-induced vomiting can cause dental problems, such as tooth enamel erosion and gum disease. Delayed stomach emptying, or gastroparesis, often develops following food restriction and weight loss; the most common symptom is bloating with gas and abdominal distension, and often occurs after eating. Other symptoms of gastroparesis include early satiety, fullness, nausea, and vomiting. The symptoms may inhibit efforts at eating and recovery, but can be managed by limiting high-fiber foods, using liquid nutritional supplements, or using metoclopramide to increase emptying of food from the stomach. Gastroparesis generally resolves when weight is regained.
Sources: en.wikipedia.org
Rhodanese is a mitochondrial enzyme that detoxifies cyanide (CN−) by converting it to thiocyanate (SCN−, also known as "rhodanate"). In enzymatology, the common name is listed as thiosulfate sulfurtransferase (EC 2.8.1.1). It catalyzes the following reaction:
Changing these amino acids to threonine (T) and alanine (A) respectively in a less stable thermolysin-like proteinase produced by Bacillus stearothermophillus (TLP-ste), results in individual reductions in stability of 7 °C (F63→T) and 6.3 °C (P69→A) and when combined a reduction in stability of 12.3 °C.
Southern: The southern section runs from the New River and consists of the prolongation of the Blue Ridge Mountains, which is divided into the Western Blue Ridge (or Unaka) Front and the Eastern Blue Ridge Front, the Ridge-and-Valley Appalachians, and the Cumberland Plateau. This same plateau is known as the Cumberland Plateau in southern West Virginia, eastern Kentucky, far Southwest Virginia, eastern Tennessee, and northern Alabama.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.